Summary of use during lactation
Prothionamide (protionamide) is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. No information is available on the use of prothionamide during breastfeeding. International sources consider breastfeeding to be acceptable during prothionamide use, but mothers should receive 100 mg of pyridoxine daily and the breastfed infant should receive pyridoxine 1 to 2 mg/kg once daily. Monitor the breastfed infant for gastrointestinal disturbances.[1]
Drug levels in milk and infant serum
Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
References
- Anon. Ethionamide (Eto) or prothionamide (Pto). MSF Medical Guidelines 2026. https://medicalguidelines.msf.org/en/viewport/TUB/english/ethionamide-eto-or-prothionamide-pto-20324029.html#section-target-3
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.